Stock Analysis

Should FDA Review of Ozekibart and INBRX-106 Data Milestones Require Action From Inhibrx (INBX) Investors?

/

Inhibrx Biosciences, Inc. reported second-quarter 2026 results, with net loss widening to US$36.65 million and basic loss per share from […]